Benzopyran Derivative - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Benzopyran Derivative

The Experts below are selected from a list of 882 Experts worldwide ranked by ideXlab platform

Yungjin Kim – One of the best experts on this subject based on the ideXlab platform.

  • KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis
    Experimental & Molecular Medicine, 2006
    Co-Authors: Shiyoung Park, Hyun Seok Song, Myung Jin Son, Sung-en Yoo, Yungjin Kim

    Abstract:

    Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angiogenesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new Benzopyran Derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.

  • kr 31831 Benzopyran Derivative inhibits vegf induced angiogenesis of huvecs through suppressing kdr expression
    International Journal of Oncology, 1992
    Co-Authors: Shiyoung Park, Sung-eun Yoo, Eunhee Seo, Hyun Seok Song, Seungyoun Jung, Youngkyoung Lee, Yungjin Kim

    Abstract:

    Angiogenesis is important in the development and progression of cancer, therefore the therapeutic approach based on anti-angiogenesis may represent a promising therapeutic option. KR-31831 is a novel anti-ischemic agent. Previously, we reported the anti-angiogenic activity of KR-31831. In the present study we investigated the molecular mechanisms underlying anti-angiogenic activity of KR-31831. We show that KR-31831 inhibits vascular endothelial growth factor (VEGF)-induced proliferation and tube formation via release of intracellular Ca 2+ and phosphorylation of extra-cellular regulated kinase 1/2 (Erkl/2) in human umbilical vein endothelial cells (HUVECs). Moreover, the expression of VEGF receptor 2 (VEGFR2, known as Flk-1 or KDR) was reduced by the treatment of KR-31831. These results suggest that KR-31831 may have inhibitory effects on tumor angiogenesis through down-regulation of KDR expression.

Shiyoung Park – One of the best experts on this subject based on the ideXlab platform.

  • KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis
    Experimental & Molecular Medicine, 2006
    Co-Authors: Shiyoung Park, Hyun Seok Song, Myung Jin Son, Sung-en Yoo, Yungjin Kim

    Abstract:

    Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angiogenesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new Benzopyran Derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.

  • kr 31831 Benzopyran Derivative inhibits vegf induced angiogenesis of huvecs through suppressing kdr expression
    International Journal of Oncology, 1992
    Co-Authors: Shiyoung Park, Sung-eun Yoo, Eunhee Seo, Hyun Seok Song, Seungyoun Jung, Youngkyoung Lee, Yungjin Kim

    Abstract:

    Angiogenesis is important in the development and progression of cancer, therefore the therapeutic approach based on anti-angiogenesis may represent a promising therapeutic option. KR-31831 is a novel anti-ischemic agent. Previously, we reported the anti-angiogenic activity of KR-31831. In the present study we investigated the molecular mechanisms underlying anti-angiogenic activity of KR-31831. We show that KR-31831 inhibits vascular endothelial growth factor (VEGF)-induced proliferation and tube formation via release of intracellular Ca 2+ and phosphorylation of extra-cellular regulated kinase 1/2 (Erkl/2) in human umbilical vein endothelial cells (HUVECs). Moreover, the expression of VEGF receptor 2 (VEGFR2, known as Flk-1 or KDR) was reduced by the treatment of KR-31831. These results suggest that KR-31831 may have inhibitory effects on tumor angiogenesis through down-regulation of KDR expression.

William F Reynolds – One of the best experts on this subject based on the ideXlab platform.

  • a prenylated Benzopyran Derivative from peperomia clusiifolia
    Phytochemistry, 1998
    Co-Authors: Navindra P. Seeram, Helen Jacobs, Stewart Mclean, William F Reynolds

    Abstract:

    The structure of a new compound, clusifoliol, isolated from whole plants of Peperomia clusiifolia has been established as 3,4-dihydro-2,7-dimethyl-6-(3-methyl-2-butenyl)-2-(4-methyl-1,3-pentadienyl)-2H-1-Benzopyran-5-ol by spectroscopic methods.